Montelukast Accord (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This stops leukotriene‑driven bronchoconstriction, mucus production, and inflammatory cell recruitment, leading to improved airway patency and reduced allergic inflammation.

The appropriate dose of Montelukast Accord is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of disease, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast during pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To order Montelukast Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast is a leukotriene receptor antagonist, whereas inhaled corticosteroids target a broader range of inflammatory pathways. Montelukast is often used as an add‑on therapy for patients whose asthma is not fully controlled with inhaled steroids, or as an alternative for those who cannot tolerate steroids. The two classes have different safety profiles and mechanisms.

Montelukast Accord should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and avoid storing them in bathrooms or other humid environments.

Montelukast Accord is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, and it may be taken with or without food. Patients should follow the dosing schedule prescribed by their clinician.

Serious risks include severe allergic reactions such as angioedema or urticaria, neuropsychiatric events like agitation, depression or suicidal thoughts, and rare hepatic abnormalities. Any signs of these conditions should prompt immediate medical evaluation.

Montelukast Accord should not be used by individuals with a known hypersensitivity to montelukast sodium or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, and it is not recommended for acute asthma attacks where rapid bronchodilation is required.